A Phase 2b, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GS 9450 in Adults With Chronic Hepatitis C Virus Infection (GS-US-227-0106)

Trial Profile

A Phase 2b, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GS 9450 in Adults With Chronic Hepatitis C Virus Infection (GS-US-227-0106)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Jan 2014

At a glance

  • Drugs Nivocasan (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 06 Nov 2012 Planned number of patients changed from 240 to 330 as reported by European Clinical Trials Database record.
    • 16 Jul 2012 This trial is recruiting in Germany.
    • 10 Jul 2012 Additional locations [Germany, United Kingdom] identified as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top